Navigation path

Pharmaceuticals - Community Register

  

Community list of not active orphan medicinal products


WITHDRAWN  

Product information

Allogeneic umbilical cord blood cells treated ex vivo with 16,16-dimethyl prostaglandin E2

EU orphan designation number: EU/3/11/867
Active ingredient: Allogeneic umbilical cord blood cells treated ex vivo with 16,16-dimethyl prostaglandin E2
Indication: Treatment of acute myeloid leukaemia
Sponsor: Fate Therapeutics, LTD
41 Chalton St, first floor, London NW1 1JD, United Kingdom

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
17/05/2011 Orphan designation EMA/OD/156/10 (2011)3493 of 13/05/2011
22/06/2015 Change of name and/or address of sponsor
29/11/2016 Removal of orphan designation from Community Register